Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma

Inclusion Criteria: * Is able to provide signed, written informed consent prior to study entry * Speaks English * compartment fasciotomy of tibial compartment * Sufficient skin for primary closure * Is male or female, 18 - 65 years of age * ABI less than 0.7, ankle pressure \< 50 mmHg, or toe pressure \< 30 mmHg. * TcPO2 \< 40 mmHg. * Female subjects must be of non childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile \[bilateral tubal ligation, bilateral oophorectomy or hysterectomy\]) or must be using adequate contraception (practicing one of the following methods of birth control): Total abstinence from sexual intercourse (minimum of one complete menstrual cycle before study entry), A partner who is physically unable to impregnate the subject (e.g., vasectomized)Contraceptives (oral, parenteral, or transdermal) for 3 consecutive months prior to patient's cell concentrate administration, Intrauterine device (IUD), or Double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream) * If female of childbearing potential, subject must have a negative urine pregnancy test at screening * Confirmation of age-appropriate cancer screening consistent with the American Cancer Society guidelines. Exclusion Criteria: * Prior compartment syndrome fracture of same limb * Previous fracture of the same limb * Any contraindication to stem cell or platelet-rich plasma therapy. * Pregnancy * Have an active malignancy or have undergone treatment for a malignancy in the preceding 5 years, with the exception of successful treatment of non-melanoma skin cancer. * Stage 4 or greater chronic kidney disease (eGFR \< 30 ml/min, MDRD estimate). * Unwilling or unable to comply with follow-up visits. * Is unable to refrain from nicotine, caffeine and alcohol for a period beginning 24 hours prior to the treatment visit * Has received an investigational medication or other study trial participation within 30 days prior to the Treatment Visit * Prisoner * Non-English Speaker